Description
An antagonist of NPY receptor Y2 (IC50s = 8.51, 6.03, and 6.17 nM for human, rat, and mouse receptors, respectively); 100-fold selective for Y2 over Y1, Y4, and Y5 receptors; inhibits calcium release induced by peptide YY in a functional assay in KAN-TS cells (pKB = 8.04); blocks NPY(13-36)-induced decreases in twitch contraction amplitude in isolated rat vas deferens (IC50 = 7.94 nM); reverses nicotine-induced social anxiety-like behavior in rats when administered during abstinence at a dose of 20 mg/kg per day, i.p., and increases hippocampal Y2 receptor mRNA levels; reverses withdrawal-induced anxiety-like behavior in rats from a single bolus dose of alcohol in the elevated plus maze when used at a dose of 15 mg/kg, s.c.; chronic administration in an olfactory bulbectomized rat model of depression decreases immobility time in the forced swim test but has no effect in control animals when used at a dose of 10 nmol per day, i.c.v.
Formal name: N,N-diethyl-4-[2-fluoro-4-[[2-(3-pyridinyl)benzoyl]amino]phenyl]-α-phenyl-1-piperazineacetamide
Synonyms:
Molecular weight: 565.7
CAS: 1094873-14-9
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Behavioral Neuroscience|Addiction Research||Research Area|Neuroscience|Behavioral Neuroscience|Anxiety||Research Area|Neuroscience|Behavioral Neuroscience|Depression
